Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,073–3,080 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Nuvalent Inc. Neladalkib (NVL-655) - (ALKAZAR) ALK-positive NSCLC Phase 3 Enrollment Initiation Oral Oncology
Nuvation Bio Inc. Class A IBTROZI (taletrectinib) - (TRUST-IV) ROS1-Positive Early-Stage Non-Small Cell Lung Cancer Phase 3 Enrollment Initiation Oral Oncology
Nuvation Bio Inc. Class A Safusidenib High-Grade IDH1-Mutant Glioma Phase 2 Enrollment Initiation oral Oncology
Nuvation Bio Inc. Class A Taletrectinib - (TRUST-I) (China) ROS1-positive non-small cell lung cancer (NSCLC) Phase 2 Data Released Oral Oncology
ObsEva Linzagolix (OBE2109) Uterine fibroids NDA Filing Oral Women's Health
ObsEva Linzagolix (OBE2109) - (PRIMROSE 1) Uterine fibroids NDA Filing Oral Women's Health
ObsEva Linzagolix (OBE2109) Uterine fibroids NDA Filing Oral Women's Health
ObsEva Linzagolix (OBE2109) - (PRIMROSE 1) Uterine fibroids NDA Filing Oral Women's Health